Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.

M. Lopez-Sublet H. Bihan G. Reach Sophie Dupont 1 A. Didelot J.-J. Mourad A. Krivitzky R. Dhote
1 NEMESIS-CRICM - Equipe NEMESIS - Centre de Recherches de l'Institut du Cerveau et de la Moelle épinière
CRICM - Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière
Abstract : Glutamic acid decarboxylase antibodies (GAD-abs) are an immunological factor involved in type 1 diabetes and other diseases involving the central nervous system. This report is of a patient with type 1 diabetes and a rare case of non-paraneoplastic limbic encephalitis mediated by anti-GAD65 antibodies that improved with the use of immunosuppressive drugs.
Document type :
Journal articles
Liste complète des métadonnées
https://hal.inria.fr/hal-00793692
Contributor : Olivier Colliot <>
Submitted on : Friday, February 22, 2013 - 5:58:12 PM
Last modification on : Thursday, March 21, 2019 - 12:26:50 PM

Identifiers

Collections

UPMC | ICM | SORBONNE-UNIVERSITE | SU-MEDECINE

Citation

M. Lopez-Sublet, H. Bihan, G. Reach, Sophie Dupont, A. Didelot, et al.. Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.. Diabetes and Metabolism, Elsevier Masson, 2012, 38 (3), pp.273-5. ⟨10.1016/j.diabet.2012.02.005⟩. ⟨hal-00793692⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

114

Contact


archive-ouverte@inria.fr